1.Long term outcome of atrial fibrillation patients with KCNA5 and NPPA mutations post circumferential pulmonary vein ablation.
Rong-feng ZHANG ; Yun-long XIA ; Chu-chu WANG ; Lian-jun GAO ; Xiao-meng YIN ; Dong CHANG ; Pei-xin CONG ; Ying-xue DONG ; Shu-long ZHANG ; Xin TU ; Qing WANG ; Yan-zong YANG
Chinese Journal of Cardiology 2013;41(5):387-389
OBJECTIVEThe outcome of atrial fibrillation patients with genetic mutations post ablation was not well evaluated.
METHODS AND RESULTSThree atrial fibrillation patients with evidence of mutations in KCNA5 and NPPA post successful circumferential pulmonary vein ablation were included. Mutation in KCNA5 was found in one male patient with paroxysmal atrial fibrillation. He was free of atrial fibrillation post ablation after 46 months follow-up. Mutations in NPPA were found in two male patients with persistent atrial fibrillation and they were free from atrial fibrillation after 64 months and 38 months follow-up post circumferential pulmonary vein ablation, roof line and mitral isthmus line ablation.
CONCLUSIONSatisfactory long term results are observed in atrial fibrillation patients with KCNA5 and NPPA mutations post circumferential pulmonary vein ablation.
Aged ; Atrial Fibrillation ; genetics ; surgery ; Atrial Natriuretic Factor ; genetics ; Catheter Ablation ; Follow-Up Studies ; Humans ; Kv1.5 Potassium Channel ; genetics ; Male ; Middle Aged ; Mutation ; Treatment Outcome
2.eNOS3 Genetic Polymorphism Is Related to Post-Ablation Early Recurrence of Atrial Fibrillation.
Jaemin SHIM ; Jae Hyung PARK ; Ji Young LEE ; Jae Sun UHM ; Boyoung JOUNG ; Moon Hyoung LEE ; Patrick T ELLINOR ; Hui Nam PAK
Yonsei Medical Journal 2015;56(5):1244-1250
PURPOSE: Previous studies have demonstrated an association between eNOS polymorphisms and atrial fibrillation (AF). We sought to determine whether eNOS polymorphisms are associated with AF recurrence after a radiofrequency catheter ablation (RFCA). MATERIALS AND METHODS: A total of 500 consecutive patients (56+/-11 years, 77% male) with paroxysmal (68%) or persistent (32%) AF who underwent RFCA and 500 age, gender-matched controls were genotyped for the eNOS3 single nucleotide polymorphism (rs1799983). AF recurrence was monitored according to 2012 ACC/AHA/ESC guidelines. RESULTS: The frequencies of the rs1799983 variant alleles (T) in the case and control group were not significantly different (OR 1.05, 95% CI 0.75-1.46, p=0.798). AF patients with rs1799983 variants were more likely to have coronary artery disease or stroke than those without genetic variant at this gene (31.0% vs. 17.3%, p=0.004). During mean 17 months follow-up, early recurrence of AF (ERAF; within 3 months) and clinical recurrence (CR) of AF were 31.8% and 24.8%, respectively. The rs1799983 variant was associated with higher risk of ERAF (OR 1.71, 95% CI 1.06-2.79, p=0.028), but not with CR. ERAF occurred earlier (11+/-16 days) in variant group than those without variant allele (20+/-25 days, p=0.016). A multiple logistic regression analysis showed that presence of the rs1799983 variant (OR 1.75, 95% CI 1.07-2.86, p=0.026) and persistent AF were independent predictors for ERAF after AF ablation. CONCLUSION: The rs1799983 variant of the eNOS3 gene was associated with ERAF, but not with CR, after RFCA. eNOS3 gene variants may have a potential role for stratification of post-ablation management.
Aged
;
Alleles
;
Atrial Fibrillation/genetics/*surgery
;
Case-Control Studies
;
*Catheter Ablation
;
Coronary Artery Disease
;
Female
;
Follow-Up Studies
;
Genotype
;
Humans
;
Logistic Models
;
Male
;
Middle Aged
;
Nitric Oxide Synthase Type III/*genetics
;
Polymorphism, Single Nucleotide/*genetics
;
Recurrence
;
Republic of Korea
;
Stroke/genetics